An article by our Chief Scientific Officer Mick Foley reviewing the emergence of next-generation antibody like therapeutics including I-bodies was published in the latest issue of European Biopharmaceutical Review (EBR).
To read the article, click here.
For the contents of the current issue of EBR, click here.
This article is taken from European Biopharmaceutical Review April 2020, pages 32-35. © Samedan Ltd